Management of intracranial tumors relies heavily on MRI of gadolinium-based contrast agents (Gd-MRI), which plays a central role in diagnosis, surgical planning, intra-surgical guidance, and post-surgical monitoring. Yet, subtotal resection rates remain high, partially due to differences in brain tissue geometry between pre-operative MRI and the surgical field. We reasoned that a nontargeted fluorescent agent that behaves similar to Gd-MRI would provide high tumor contrast, image information familiar to neurosurgeons and alleviate the need to coordinate administration hours before surgery common to other fluorescent agents. We screened several candidate agents in tumor-bearing animals using hyperspectral whole animal fluorescence cryo-tomography and co-registered MRI. This approach enabled evaluation of agent distribution at high resolution in three dimensions and comparison of agents against Gd-MRI. We identified a lead agent that provides high tumor contrast and diagnostic performance within minutes of administration and was highly correlated to the co-registered Gd-MRI volumes. In this presentation, I will review the performance of this agent in small and large animal models.
|